Member Info for OTUP

I thought VAL301 was expected to be the first with news? VAL301 is a 'Small molecule, peptide, New Chemical Entity (NCE), VAL201 peptide re-purposed towards non-cancerous cell proliferation' . So the VAL301 for Endometriosis is more inline with the one core mission of the business in womens health, derived from 201 - how many more non oncological derivatives could their be? I can't really see this RNS as a major killer for the Market cap of the company, they lose nothing but time if TheoremRx don't sign as the deal on VAL 301 will easily fund working capital for the business when it comes, and the way it has been discussed its a when not an if

Sorry I was responding to righback who said their response to my question would have been ruder than yours. I understand your response, but do not see the link between pathcelerate and other organisations. This is where I lack experience to research.

No need to imply offence to novices. If i knew as much as you I too would be a multi millionaire - unfortunately I am not, but this board and investment markets are not exclusively for experts like yourself.

I find this board as many others to be taken lightly, when people talk about T1 level resistance etc for most companies they might as well see all the chart levels of bitcoin as the results are the same - absolute twoddle.
However I have to ask the question regarding Pathcelerate and Adam Hargreaves, Why do they own £550K in VAL when their last balance sheet only had £500k capital? Have they had a nod to plan preclinical trials and safety assessments?

With Institutional investors having significant stakes, the Fowler family need to be extra cautious and be more aware of honest disclosure, the big boys will take no S...!

Did the RNS say they are currently operating at 50% at the airports? I just checked Flight Trader and there are currently 5 planes in DRC air space???????????? And they may not have taken off from DRC - are we being hoodwinked again??

Did the RNS say they are currently operating at 50% at the airports? I just checked Flight Trader and there are currently 5 planes in DRC air space????????????

There is a huge difference between 'at cost' and non profit - accountants will understand that!

yes - less costs - but should make the current share price an absolute bargain - hang on get another 5 dividends then take the profit!

Results next month but already in line with 5 year expansion plan. No chat on here as the market is not one that a lot of people who are familiar with. But the countries that it operates in are like anywhere else - mobile phones are more important than a lot of lifes essentials, therefore the market for expanding networks is sold.

So employee ratio to board members is 37-1. G4S is a ratio of 4000-1

which comes to over £910000 with bonuses and benefits for a company that turns £10m. The other 261 empoyees got 4x what the board got or £16.8k each.

Must admit I dont know how old Joanna is but Peter can retire at anytime, plenty of raises have ensured a stable retirement. The board of this company gets paid almost 10% of revenue cant be many listed companies that take that slice for themselves. Also no stipulation on exec directors share holding - senior leaders and directors normally have a minimum salary multiple - this would make them think twice about diluting as it would cost them!!!!!!

Unfortunately that will never happen as The Fowlers think its their company, shareholders are answerable to them????? They started taking the share price from 80p to 10p from 2009 then from 95p to 4p from 2014 - these huge peaks were born from smelly stuff found in a field.

So while air transport has been on its knees for 9 months, WSG have been negotiating some plum deals to provide security for airports? This is the worst stunt the Fowler family have pulled and if the truth was all out, probably illegal - just another raise to pay their wages. If Stuart takes early retirement at 50 - they only have another 5 years of raises to go until they are all out!

Pysiomics seem to have possible impacts in a lot of fields - Valrix stated on their initial study of the VAL201 for prostate cancer that one patient showed toxic effects down to the dosage being too high - another area for PYC to step in and optimise!

Interesting. Today said that half a dose followed by a full dose had better effect than 2 full doses a month apart - don't Physiomics model optimum dosages of medicine or would this be completely tied to oncology drugs, I would think more tied to data than the type of drug. But strong ties to oxford University for Physiomics and the vaccine.
No doubt there will be some more informed opinion than mine which I would apreciate seeing.

The continual addition of new contracts will make this stock a reasonable and steady investment. However the level of success the modelling gives to clients will never be in the public arena. After all GSK are hardly likely to announce the approval of a new drug and mention a 3rd party being responsible for its achieving approval significantly quicker than normal. If this was the case PYC would be snapped up well before the event and if any competition to purchase was seen £100m would still be chicken feed for this kind of benefit in the Pharma world. So the question remains, really how good is this modelling process?

However if you look at their slides for todays presentation they say exclusively cancer.

With 70m shares in issue and over 35m traded this morning ........ how unusual is this, I have not come across this proportion of trades before?